NCT01237457已完成2 期
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Ebrahim S Delpassand1 个研究点 分布在 1 个国家目标入组 143 人开始时间: 2010年10月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 143
- 试验地点
- 1
- 主要终点
- Progression Free survival
研究概览
简要总结
This is a phase II treatment protocol evaluating 177Lu-DOTATATE therapy for somatostatin receptor-expressing cancers including, but not limited to, those arising from the neural crest and involving such organs as the lungs, breast, gastrointestinal tract, skin, and endocrine (examples: pheochromocytoma, medullary carcinoma of the thyroid, non-radioiodine avid differentiated thyroid cancer, melanoma, renal cell, Merkel cell, paraganglioma, small cell lung, Carcinoid, and pancreatic islet cell malignancies).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with biopsy proven Gastroenteropancreatic (GEP tumors including bronchial carcinoids)
- •Presence of somatostatin-receptors on the known tumor lesions demonstrated by OctreoScan within 6 months of the first dose of radiolabelled octreotate therapy. The uptake on the OctreoScan should be at least as high as normal liver uptake on planar imaging.
- •Life Expectancy greater than 12 weeks.
- •Serum creatinine ≤ 150 µmol/liter or 1.7 mg/dL and a measured creatinine clearance (or measured GFR using plasma clearance methods, not gamma camera based) of ≥ 50ML/min.
- •Hemoglobin (Hgb) concentration ≥ 5.5 mmol/L (≥ 8.9 g/dL); WBC ≥ 2*109/L (2000/mm3); platelets ≥ 100*109/L (100*103/mm3).
- •Total Bilirubin ≤ 3X UNL.
- •Serum Albumin > 30g/L or serum albumin ≤ 30g/L but normal prothrombin time.
- •All patients must have a Karnofsky performance status of at least 60%
- •Patients must be greater than 18 years of age. Patients younger than 18 years will be presented to FDA for compassionate use on a case by case basis
排除标准
- •Possible surgery with curative intent.
- •Surgery, radiotherapy, chemotherapy or other investigational therapy within 3 months of the start of therapy.
- •Patients with known brain metastases unless these metastases have been treated and stabilized for at least 6 months prior to study start. Patients with a history of brain metastases must have a head CT with contrast to document stable disease prior to study start.
- •Uncontrolled congestive heart failure.
- •Any subject who is taking concomitant medications which decrease renal function (such as aminoglycoside antibiotics).
- •Any subject receiving therapy with somatostatin analogues, unless the dose has been stable for at least 3 months prior to the first cycle in this study and the disease status during these 4 months has been documented by modified RECISTS criteria as described in this study
- •Any subject receiving therapy with short acting somatostatin analogues in whom these analogues cannot be interrupted for 12 hours before and 12 hours after the administration of the radio labelled somatostatin analogues, or any subject who receives therapy with long-acting somatostatin analogues in whom these analogues cannot be interrupted for at least 6 weeks before the administration of the radio labeled somatostatin analogues, unless the uptake on the Octreoscan during continued somatostatin analogue medication is at least as high as normal liver uptake on planar imaging.
- •In patients with unusual hematological parameters, including an increased MCV (>105fL), and especially in those who had previous chemotherapy, the advice of a hematologist should be sought for adequate further work-up.
- •Subjects with another significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with completion of the study.
- •Prior radiation therapy to more than 25% of the bone marrow.
- •Female patients who are pregnant, lactating or women of childbearing potential not willing to practice effective contraceptive techniques during the study period and for 60 days (10 half lives of 177Lu after the last treatment, or male patients who have female partners of childbearing potential not willing to practice abstinence or effective contraception, during the study period and for 60 days after the last treatment
研究组 & 干预措施
Treatment
Experimental
Patients with somatostatin receptor-expressing neuroendocrine neoplasms will receive up to 200 mCi of 177Lu-DOTATATE every 6-11 weeks, preferably 6-9 weeks to a cumulative dose of 800 mCi.
干预措施: 177Lu-DOTATATE (Drug)
结局指标
主要结局
Progression Free survival
时间窗: one year after completion of last treatment cycle
Overall response will be determined by Progression Free Survival (PFS). PFS will be calculated as a function of time from start of therapy to time of overall disease progression. Patients will be censored at the date of last contact
次要结局
- Dose limiting toxicity(one year after completion of the fourth cycle of treatment)
研究者
Ebrahim S Delpassand
Chairman and Medical Director
Excel Diagnostics and Nuclear Oncology Center
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.Pulmonary Neuroendocrine NeoplasmThymus CarcinoidUnknown Primary TumorsNeuroendocrine TumorsNeuroendocrine Skin CarcinomaNeuroendocrine Breast TumorNeuroendocrine Carcinoma MetastaticNeuroendocrine Neoplasm of OvaryPheochromocytomaParagangliomaNCT04276597Excel Diagnostics and Nuclear Oncology Center
已完成
2 期
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)Neuroendocrine TumorsMedulloblastomaNeuroblastomaMeningiomaNCT03273712University of Iowa39
撤回
2 期
Dosimetry Guided PRRT With 90Y-DOTATOCNeuroendrocrine TumorsMedulloblastomaMeningiomaNeuroblastomaNCT03013387Sue O'Dorisio
招募中
2 期
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialNCT05773274National Cancer Institute (NCI)100
已完成
不适用
Somatostatin Receptor Imaging in Patients With Suspected Cardiac SarcoidosisSarcoidosisNCT02546388Marcelo F. Di Carli, MD, FACC17